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Abstract
In POLLUX, daratumumab (D) plus lenalidomide/dexamethasone (Rd) reduced the risk of disease progression or death by
63% and increased the overall response rate (ORR) versus Rd in relapsed/refractory multiple myeloma (RRMM). Updated
efficacy and safety after >3 years of follow-up are presented. Patients (N= 569) with ≥1 prior line received Rd
(lenalidomide, 25 mg, on Days 1–21 of each 28-day cycle; dexamethasone, 40 mg, weekly) ± daratumumab at the approved
dosing schedule. Minimal residual disease (MRD) was assessed by next-generation sequencing. After 44.3 months median
follow-up, D-Rd prolonged progression-free survival (PFS) in the intent-to-treat population (median 44.5 vs 17.5 months;
HR, 0.44; 95% CI, 0.35–0.55; P < 0.0001) and in patient subgroups. D-Rd demonstrated higher ORR (92.9 vs 76.4%;
P < 0.0001) and deeper responses, including complete response or better (56.6 vs 23.2%; P < 0.0001) and MRD negativity
(10–5; 30.4 vs 5.3%; P < 0.0001). Median time to next therapy was prolonged with D-Rd (50.6 vs 23.1 months; HR, 0.39;
95% CI, 0.31–0.50; P < 0.0001). Median PFS on subsequent line of therapy (PFS2) was not reached with D-Rd versus
31.7 months with Rd (HR, 0.53; 95% CI, 0.42–0.68; P < 0.0001). No new safety concerns were reported. These data support
using D-Rd in patients with RRMM after first relapse.
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Introduction
The development of first- and second-generation novel
agents over the past decade has led to the acceptance of
immunomodulatory drug (IMiD)–based or proteasome
inhibitor (PI)–based doublet or triplet therapy as standard of
care for newly diagnosed and relapsed or refractory multiple
myeloma (RRMM) [1, 2]. However, multiple myeloma
(MM) remains an incurable disease, underscoring the need
for new treatment strategies. Optimal combination and
sequencing of these next-generation agents remain to be
defined, particularly among various patient subgroups.
Daratumumab is a human immunoglobulin Gκ mono-
clonal antibody targeting CD38 with a direct on-tumor
[3–6] and immunomodulatory mechanism of action [7–9].
Daratumumab-induced on-tumor activity occurs through
several CD38 immune-mediated actions (complement-
dependent cytotoxicity, antibody-dependent cellular
cytotoxicity, and antibody-dependent cellular phagocy-
tosis), apoptosis, and modulation of CD38 enzymatic
activity [3–6]. The immunomodulatory actions of dar-
atumumab minimize the immune-suppressive functions of
CD38+ myeloid-derived tumor suppressor cells, reg-
ulatory T cells, and regulatory B cells and increase T-cell
clonality [7–9].
Daratumumab has demonstrated single-agent activity in
heavily pretreated RRMM and in combination with
standard-of-care regimens in RRMM after at least one prior
therapy [10–13]. Daratumumab safety and efficacy are also
established in combination with bortezomib, melphalan,
and prednisone, and with lenalidomide and dexamethasone
in patients with newly diagnosed MM (NDMM) who are
transplantation ineligible [14, 15].
In the prespecified interim analysis of the phase 3
POLLUX study (median follow-up, 13.5 months), dar-
atumumab in combination with lenalidomide and dex-
amethasone (D-Rd) reduced the risk of disease
progression or death by 63% (median progression-free
survival [PFS] not reached vs 18.4 months; hazard ratio
[HR], 0.37; 95% confidence interval [CI], 0.27–0.52; P <
0.001) and significantly increased the overall response
rate (ORR) compared with lenalidomide and dex-
amethasone (Rd) alone (93 vs 76%; P < 0.001) in patients
with at least one prior therapy [12]. In an updated analysis
after a longer follow-up of 25.4 months, the PFS benefit of
D-Rd was maintained compared with Rd, with median
PFS still not being reached for D-Rd versus 17.5 months
for Rd. In addition, deep and durable responses were
achieved with D-Rd, and the PFS benefit of D-Rd versus
Rd was consistently maintained regardless of the number
of prior lines of therapy received, prior IMiD exposure,
bortezomib refractoriness, time since last therapy, or
cytogenetic risk [16].
We report the long-term efficacy and safety analyses of
POLLUX after a median follow-up of more than
3.5 years.
Subjects and methods
Study design and patients
POLLUX is an ongoing, randomized, open-label, multi-
center, phase 3 study in patients with RRMM (Clin-
icalTrials.gov Identifier: NCT02076009). An independent
ethics committee or institutional review board at each site
approved the trial, and all patients provided written
informed consent. The study protocol was conducted in
accordance with the principles of the Declaration of Hel-
sinki and the International Conference on Harmonisation
Good Clinical Practice guidelines. The study design, pri-
mary results, and post hoc secondary analyses have been
previously reported [12, 16]. Briefly, eligible patients had
progressive disease (according to International Myeloma
Working Group [IMWG] criteria) [17, 18] during or after
their last regimen, received and responded to at least
one prior line of therapy, and had a creatinine clearance
≥30 mL/min. Prior lenalidomide exposure was allowed, but
patients with lenalidomide-refractory disease were excluded
from participation. A total of 569 patients were randomly
assigned (1:1) using an interactive web response system to
Rd (lenalidomide: 25 mg orally on Days 1–21 of each 28-
day cycle; dexamethasone: 40 mg orally weekly) with or
without daratumumab (16 mg/kg intravenous weekly for
8 weeks, every 2 weeks for 16 weeks, and every 4 weeks
thereafter) until progression. The randomization was
balanced by using randomly permuted blocks and was
stratified by International Staging System (ISS), number of
prior lines of therapy (1 vs 2 or 3 vs >3), and prior lenali-
domide exposure. Treatment assignments were not blinded.
Endpoints and assessments
The primary efficacy endpoint was PFS. Secondary efficacy
endpoints included ORR, rates of very good partial
response (VGPR) or better and complete response (CR) or
better, minimal residual disease (MRD), time to response,
duration of response, and overall survival (OS). PFS on
subsequent line of therapy (PFS2) was an exploratory
endpoint and was defined as the time from randomization to
progression after the next line of subsequent therapy
or death.
Exploratory post hoc secondary analyses evaluated
patient subgroups according to prior lines of therapy (1 and
1–3), prior lenalidomide treatment, refractoriness to borte-
zomib, and achievement of CR or better. The number of
N. J. Bahlis et al.
prior lines of therapy was determined by investigators
according to the IMWG consensus guidelines [18]. PFS,
ORR, and MRD negativity were assessed for each
subgroup.
MRD was assessed at the time of suspected CR and at 3
and 6 months after confirmed CR (and every 12 months
thereafter if CR was maintained) using clonoSEQ® V2.0
(Adaptive Biotechnologies, Seattle, WA, USA). To allow
for stringent, unbiased MRD evaluation, the entire intent-to-
treat (ITT) population was evaluated, and patients were
considered MRD positive if they had MRD-positive test
results or no MRD assessment.
Statistical analyses
Statistical analyses have been described previously [12].
Approximately 560 patients were randomized to observe
295 PFS events to detect an HR of 0.7 for the D-Rd group
relative to the Rd group with 85% power at a two-sided
significance level of 0.025, using a group sequential testing
design.
PFS was compared between treatment groups based on
a stratified log-rank test. HRs and 95% CIs were estimated
using a stratified Cox regression model with treatment as
the sole explanatory variable, and the Kaplan–Meier
method was used to estimate the distributions. Stratified
Cochran–Mantel–Haenszel tests were used to test treat-
ment differences in ORRs and rates of VGPR or better and
CR or better. MRD-negative rates were compared between
groups using a Fisher’s exact test and the likelihood-
ratio test.
Results
Between June 16, 2014 and July 14, 2015, 569 patients at
135 sites in 18 countries across North America, Europe,
and the Asia Pacific region were randomly assigned in
POLLUX; 286 patients were assigned to D-Rd and 283
patients were assigned to Rd. Baseline patient demo-
graphics, prior treatment history, and other clinical and
cytogenetic characteristics have been previously published
[12, 16] and are summarized in Supplementary Table 1.
Approximately half of patients (52%) had received one
prior line of therapy, 18% had received prior lenalidomide,
44% had received prior IMiD and PI, and 21% were
refractory to bortezomib.
At the clinical cutoff on October 10, 2018, a total of 158
(55.8%) patients in the D-Rd group and 237 (84.3%)
patients in the Rd group had discontinued treatment. The
most common reasons for discontinuation of treatment were
progressive disease (D-Rd, 33.2%; Rd, 59.4%) and adverse
events (AEs; D-Rd, 14.8%; Rd, 14.9%). The median
(range) duration of study treatment was 34.3 (0–50.8)
months in the D-Rd group and 16.0 (0.2–50.5) months in
the Rd group.
Efficacy
For the primary endpoint, at a median (range) follow-up of
44.3 (0–50.9) months, D-Rd significantly prolonged PFS
compared with Rd in the ITT population (median 44.5 [95%
CI, 34.1–not estimable] vs 17.5 [95% CI, 13.9–20.8]
months; HR, 0.44; 95% CI, 0.35–0.55; P < 0.0001; Fig. 1a).
In the subgroup of patients who received one prior line of
therapy, D-Rd (n= 149) significantly prolonged PFS versus
Rd (n= 146; median not reached vs 19.6 months; HR, 0.42;
95% CI, 0.30–0.58; P < 0.0001; Fig. 1b); 42-month PFS
rates were 57.3% versus 27.8%, respectively. Among
patients who received one to three prior lines of therapy,
D-Rd (n= 272) significantly prolonged PFS versus Rd
(n= 264; median 44.5 vs 17.5 months; HR, 0.43; 95% CI,
0.34–0.54; P < 0.0001). In patients who achieved deep
responses of CR or better, PFS was prolonged with D-Rd
(n= 159) versus Rd (n= 64), with 42-month PFS rates of
73.6% versus 59.6%, respectively; Fig. 1c. In patients with
prior lenalidomide therapy, PFS was significantly prolonged
with D-Rd (n= 50) versus Rd (n= 50; median 38.8 vs
18.6 months; HR, 0.38; 95% CI, 0.21–0.66; P= 0.0004;
Fig. 1d). In the subset of patients with bortezomib-
refractory disease, PFS was significantly prolonged with
D-Rd (n= 59) versus Rd (n= 58; median 34.3 vs
11.3 months; HR, 0.40; 95% CI, 0.24–0.67; P= 0.0003;
Fig. 1e). The PFS benefit of D-Rd versus Rd was also
maintained in patients who received two or three lines of
prior therapy, and in subgroups based on cytogenetic risk
status, age, type of MM, ISS disease stage, Eastern Coop-
erative Oncology Group performance status score, baseline
renal or hepatic function, prior treatment exposure, and
refractory status (Fig. 2).
In the response-evaluable population, ORR was sig-
nificantly higher with D-Rd (n= 281) compared with Rd
alone (n= 276; 92.9 vs 76.4%; P < 0.0001; Table 1),
including higher rates of VGPR or better (80.4 vs 49.3%;
P < 0.0001) and CR or better (56.6 vs 23.2%; P < 0.0001).
Stringent CRs were achieved in 29.2% of patients in the
D-Rd group versus 10.5% of patients in the Rd group.
Among patients who received prior lenalidomide, ORR was
significantly higher with D-Rd (n= 50) compared with Rd
alone (n= 47; 84.0 vs 64.0%; P= 0.0233; Table 1),
including higher rates of VGPR or better (80.0 vs 36.0%;
P < 0.0001), CR or better (54.0 vs 12.0%; P < 0.0001), and
stringent CR (26.0 vs 2.0%). At a sensitivity threshold of
10−5, MRD negativity was achieved by 87 (30.4%) patients
in the ITT population who received D-Rd versus 15 (5.3%)
patients who received Rd (P < 0.0001). Among patients
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Fig. 1 PFS in the ITT population and in patient subgroups based
on prior treatment. PFS in (a) the ITT populationa and in patients
with (b) one prior line of therapy, (c) responses of CR or better,
(d) prior lenalidomide exposure, or (e) refractoriness to bortezomib.
Kaplan–Meier estimates of PFS. PFS, progression-free survival;
ITT, intent-to-treat; D-Rd, daratumumab/lenalidomide/dexamethasone;
Rd, lenalidomide/dexamethasone; HR, hazard ratio; CI, confidence
interval; NE, not estimable. aThe upper bound of the 95% CI is
currently NE.
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who achieved MRD negativity (10−5), PFS was prolonged
with D-Rd versus Rd (median not reached vs 42.0 months;
HR, 0.46; 95% CI, 0.19–1.08; P= 0.0667; Fig. 3), with
42-month PFS rates of 76.7% with D-Rd and 42.8% with
Rd. Among patients with MRD-positive status, D-Rd sig-
nificantly prolonged PFS compared with Rd (median 29.4
vs 16.0 months; HR, 0.60; 95% CI, 0.48–0.76; P < 0.0001;
Fig. 3). Among patients who received prior lenalidomide, a
similar improvement in the rate of MRD negativity (10−5)
was observed with D-Rd (32.0%) versus Rd alone (6.0%;
P= 0.0006).
Median duration of response was not reached (95% CI,
could not be estimated) with D-Rd compared with 25.2
(95% CI, 19.3–29.7) months with Rd. Median time to next
therapy was 50.6 months versus 23.1 months in the D-Rd
and Rd arms, respectively (HR, 0.39; 95% CI, 0.31–0.50;
P < 0.0001; Fig. 4a). A total of 63 patients in the Rd group
received daratumumab monotherapy after disease progres-
sion on Rd. At the time of this analysis, seven patients were
on subsequent daratumumab monotherapy. The most com-
mon reason for discontinuation of daratumumab mono-
therapy was disease progression. Median PFS2 was not
HR
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Fig. 2 PFS in patient subgroups. PFS, progression-free survival;
D-Rd, daratumumab/lenalidomide/dexamethasone; Rd, lenalidomide/
dexamethasone; CI, confidence interval; NE, not estimable;
ISS, International Staging System; MM, multiple myeloma; Ig,
immunoglobulin; ECOG, Eastern Cooperative Oncology Group;
CrCl, creatinine clearance; PI, proteasome inhibitor; FISH, fluorescence
in situ hybridization. aImpaired hepatic function included mild, mod-
erate, and severe hepatic dysfunction as per National Cancer Institute
organ dysfunction criteria. bCytogenetic risk was determined by FISH
or karyotyping. cPatients with high cytogenetic risk had t(4;14),
t(14;16), or del17p abnormalities.
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reached in the D-Rd group versus 31.7 months in the Rd
group (HR, 0.53; 95% CI, 0.42–0.68; P < 0.0001; Fig. 4b),
with 42-month PFS2 rates of 59% and 38%, respectively.
At the time of this analysis, fewer deaths occurred in
patients receiving D-Rd (n= 104) compared with Rd (n=
121), and median OS was not reached in either group. The
42-month OS rate was 65% with D-Rd versus 57% with Rd.
Follow-up for OS is ongoing.
Safety
No new safety concerns were reported in either treatment
group with longer follow-up. The most common treatment-
emergent AE (TEAE) was neutropenia, occurring in 63.3%
of patients treated with D-Rd and 48.0% of patients who
received Rd (Table 2). The most common (≥5%) grade 3/4
TEAEs observed with D-Rd and Rd included neutropenia,
febrile neutropenia, anemia, thrombocytopenia, lymphope-
nia, pneumonia, diarrhea, fatigue, hypokalemia, and catar-
acts (Table 2). The percentage of patients with TEAEs
leading to treatment discontinuation was similar between
groups (D-Rd, 14.8; Rd, 14.6%). The most common TEAEs
(≥1%) leading to treatment discontinuation with D-Rd
versus Rd were pneumonia (1.8 vs 1.1%), pulmonary
embolism (0 vs 1.1%), septic shock (1.1 vs 0%), and gen-
eral physical health deterioration (1.1 vs 0%), respectively.
The incidence of second primary malignancies was similar
between groups, occurring in 8.5% of patients who received
D-Rd and 8.9% of patients who received Rd (Table 3).
Discussion
After >3.5 years of median follow-up, the addition of dar-
atumumab to Rd continued to demonstrate significant
clinical benefit over Rd alone in patients with RRMM. At a
median follow-up of 44.3 months, D-Rd demonstrated an
unprecedented median PFS of 44.5 months versus only
17.5 months for Rd, conferring a 56% reduction in the risk
of disease progression or death. At the time of the analysis,
the upper bound of the 95% CI for median PFS in the D-Rd
group was not estimable. Deep responses, including sig-
nificantly higher (>5-fold) rates of MRD negativity (10–5)
0
No. at risk
Rd MRD negative
D-Rd MRD negative
Rd MRD positive
D-Rd MRD positive
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Fig. 3 PFS based on MRD status (10–5). PFS, progression-free sur-
vival; MRD, minimal residual disease; D-Rd, daratumumab/lenalido-
mide/dexamethasone; Rd, lenalidomide/dexamethasone.
Table 1 Summary of best confirmed responsea and MRD-negativeb
rates.
Variable D-Rd (n= 281) Rd (n= 276) P
Overall response
No. with response 261 211
Rate, % (95% CI) 92.9
(89.2–95.6)
76.4
(71.0–81.3)
< 0.0001c
Clinical benefit, n (%)d 266 (94.7) 237 (85.9)
Best overall response, n (%)
CR or better 159 (56.6) 64 (23.2) < 0.0001c
Stringent CRe 82 (29.2) 29 (10.5)
CR 77 (27.4) 35 (12.7)
VGPR or better 226 (80.4) 136 (49.3) < 0.0001c
VGPR 67 (23.8) 72 (26.1)
Partial response 35 (12.5) 75 (27.2)
Stable diseasef 18 (6.4) 59 (21.4)
Progressive disease 0 (0.0) 4 (1.4)
Response could not
be evaluated
2 (0.7) 2 (0.7)
MRD negative (10−5) n= 286 n= 283
n (%) 87 (30.4) 15 (5.3) < 0.0001g
Response was assessed according to the Uniform Criteria Consensus
recommendations of the International Myeloma Working Group
[17, 18]. The analysis included patients who had a confirmed
diagnosis of MM and measurable disease at baseline or screening. In
addition, patients had received at least one administration of trial
treatment and had at least one disease assessment after the
baseline visit.
MRD minimal residual disease, D-Rd daratumumab/lenalidomide/
dexamethasone, Rd lenalidomide/dexamethasone, CI confidence
interval, CR complete response, VGPR very good partial response.
aResponse-evaluable population.
bIntent-to-treat population.
cP value was calculated using the Cochran–Mantel–Haenszel chi-
square test.
dClinical benefit includes all patients with minimal response, partial
response, VGPR, CR, and stringent CR.
eCriteria for a stringent CR include the criteria for a CR plus a normal
free light-chain ratio and the absence of clonal plasma cells as assessed
by immunohistochemical or immunofluorescence analysis or by flow
cytometry.
fIncludes patients who achieved a minimal response.
gP value was calculated using the Fisher’s exact test.
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were achieved with D-Rd versus Rd alone (30.4 vs 5.3%,
respectively), which deepened with longer follow-up [16].
Patients with one prior line of therapy gained the
greatest clinical benefit with D-Rd, resulting in a 58%
reduction in the risk of disease progression or death
compared with Rd. Consistent findings were observed in
CASTOR, in which patients who received one prior line
of therapy demonstrated the greatest clinical benefit
with daratumumab plus bortezomib and dexamethasone
(D-Vd) versus bortezomib and dexamethasone (Vd) alone
(78% reduction in the risk of disease progression or
death), regardless of prior treatment with either lenalido-
mide or bortezomib [19].
In POLLUX, patients who were refractory to lenalido-
mide were excluded from the study. However, D-Rd
demonstrated improved efficacy outcomes, including pro-
longed PFS and improved depth of response in patients who
received prior lenalidomide but were not refractory to the
drug. Furthermore, D-Rd prolonged PFS versus Rd in poor
prognostic patient subgroups, including those with ISS
stage III disease, patients who were refractory to their last
prior line of therapy, and patients with high cytogenetic risk
abnormalities, although to a lesser extent in comparison
with other patient subgroups evaluated.
Although cross-study comparisons must take into
account differences in study population and design, the
median PFS observed with D-Rd (44.5 months) is unpre-
cedented in the RRMM treatment setting. In the phase 3
ASPIRE study of carfilzomib plus Rd (KRd) compared with
Rd alone in patients with relapsed MM and one to three
prior treatments, median PFS was 26.1 versus 16.6 months
with KRd and Rd, respectively (HR, 0.66; 95% CI,
0.55–0.78; P < 0.001), at a median follow-up of
48.8 months for KRd and 48.0 months for Rd [20]. With
longer follow-up (median 67.1 months), median OS was
48.3 months for KRd versus 40.4 months for Rd, resulting
in 21% reduction in the risk of death (HR, 0.79; 95% CI,
0.67–0.95; P= 0.0045) [20]. In the phase 3
TOURMALINE-MM1 study in patients with RRMM and
one to three prior therapies, median PFS was 20.6 months
with ixazomib in combination with Rd (IRd) versus
14.7 months with Rd alone (HR, 0.74; 95% CI, 0.59–0.94;
P= 0.01), at a median follow-up of 14.8 versus
14.6 months in the IRd and Rd groups, respectively [21].
Median PFS in the phase 3 ELOQUENT-2 study in patients
with RRMM and one to three prior therapies was
19.4 months with elotuzumab plus Rd compared with
14.9 months with Rd alone (HR, 0.73; 95% CI, 0.60–0.89;
P= 0.0014), with 3 years of extended follow-up [22].
D-Rd induced deep and durable responses that continued
to deepen over time with longer follow-up. At the most
recent clinical cutoff, rates of VGPR or better (80.4 vs
49.3%) and CR or better (56.6 vs 23.2%) with D-Rd versus
Rd were higher than those observed at primary analysis
(VGPR or better: 75.8 vs 44.2%; CR or better: 43.1 vs
19.2%) [12] and at ~2 years of follow-up (VGPR or better:
78.6 vs 47.8%; CR or better: 51.2 vs 21.0%; Supplementary
Fig. 1a) [16]. MRD-negative rates have also continued to
deepen with D-Rd versus Rd over time (interim analysis:
22.4 vs 4.6% [12]; 2-year follow-up: 26.2 vs 6.4% [16];
current analysis: 30.4 vs 5.3%; Supplementary Fig. 1b),
while the rates of MRD negativity with Rd have remained
relatively constant with longer follow-up. It is important to
note that an updated next-generation sequencing assay with
improved calibration rate was used to determine MRD
negativity in the current study. PFS was prolonged with
0
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Fig. 4 Time to subsequent therapy and PFS2. Time to subsequent
therapy (a) and PFS2 (b) in the ITT population. PFS2, progression-
free survival on subsequent line of therapy; HR, hazard ratio;
CI, confidence interval; Rd, lenalidomide/dexamethasone;
D-Rd, daratumumab/lenalidomide/dexamethasone; ITT, intent-to-treat.
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D-Rd versus Rd in patients who achieved MRD negativity
and significantly prolonged with D-Rd versus Rd in patients
with MRD-positive status. The lack of a statistically sig-
nificant difference in PFS among patients who achieved
MRD negativity with D-Rd versus Rd (P= 0.0667) may
be the result of the low number of patients in the Rd arm
(n= 15).
PFS2 may serve as a surrogate endpoint for OS when
survival data are not available [23]. The use of PFS2 has
been suggested as a preferred endpoint, particularly for
studies investigating long-term maintenance treatment
[23–25]. The findings presented here demonstrate that D-Rd
significantly prolongs the time to subsequent therapy and
PFS2 versus Rd, conferring a 47% reduction in the risk of
disease progression or death on the next line of therapy.
These data indicate that treatment with D-Rd does not
negatively impact on patient outcomes on subsequent
therapy. At the time of this analysis, 17 more deaths
occurred with Rd (121/283) compared with D-Rd (104/
286). Follow-up for OS in POLLUX is ongoing, with the
final analysis planned after 330 deaths.
Table 2 Most common all grade
(≥25%) and grade 3/4 (≥5%)
TEAEs in the safety population.
Event D-Rd (n= 283) Rd (n= 281)
All grade, n (%) Grade 3/4, n (%) All grade, n (%) Grade 3/4, n (%)
Total 281 (99.3) 255 (90.1) 274 (97.5) 227 (80.8)
Hematologic
Neutropenia 179 (63.3) 157 (55.5) 135 (48.0) 117 (41.6)
Febrile neutropenia 18 (6.4) 18 (6.4) 8 (2.8) 8 (2.8)
Anemia 111 (39.2) 50 (17.7) 114 (40.6) 60 (21.4)
Thrombocytopenia 87 (30.7) 42 (14.8) 88 (31.3) 44 (15.7)
Lymphopenia 19 (6.7) 16 (5.7) 17 (6.0) 12 (4.3)
Nonhematologic
Diarrhea 165 (58.3) 28 (9.9) 105 (37.4) 11 (3.9)
Upper respiratory tract
infection
121 (42.8) 5 (1.8) 78 (27.8) 5 (1.8)
Fatigue 110 (38.9) 19 (6.7) 87 (31.0) 12 (4.3)
Cough 99 (35.0) 1 (0.4) 42 (14.9) 0 (0.0)
Nasopharyngitis 96 (33.9) 0 (0.0) 59 (21.0) 0 (0.0)
Constipation 93 (32.9) 3 (1.1) 76 (27.0) 2 (0.7)
Muscle spasms 84 (29.7) 3 (1.1) 60 (21.4) 4 (1.4)
Nausea 82 (29.0) 6 (2.1) 51 (18.1) 2 (0.7)
Insomnia 76 (26.9) 6 (2.1) 63 (22.4) 4 (1.4)
Pyrexia 73 (25.8) 9 (3.2) 40 (14.2) 7 (2.5)
Back pain 71 (25.1) 8 (2.8) 57 (20.3) 5 (1.8)
Pneumonia 71 (25.1) 43 (15.2) 46 (16.4) 28 (10.0)
Edema peripheral 67 (23.7) 2 (0.7) 47 (16.7) 4 (1.4)
Vomiting 62 (21.9) 3 (1.1) 19 (6.8) 4 (1.4)
Dyspnea 61 (21.6) 12 (4.2) 37 (13.2) 2 (0.7)
Bronchitis 57 (20.1) 7 (2.5) 48 (17.1) 9 (3.2)
Asthenia 54 (19.1) 10 (3.5) 46 (16.4) 9 (3.2)
Cataract 54 (19.1) 17 (6.0) 33 (11.7) 12 (4.3)
Hypokalemia 51 (18.0) 17 (6.0) 31 (11.0) 9 (3.2)
Headache 49 (17.3) 0 (0.0) 24 (8.5) 0 (0.0)
TEAE treatment-emergent adverse event, D-Rd daratumumab/lenalidomide/dexamethasone, Rd lenalido-
mide/dexamethasone.
Table 3 Summary of second primary malignancies in the safety
population.
D-Rd (n= 283) Rd (n= 281)
Total, n (%) 24 (8.5) 25 (8.9)
Cutaneous/noninvasive 12 (4.2) 10 (3.6)
Noncutaneous/invasive 8 (2.8) 11 (3.9)
Hematologic 5 (1.8) 3 (1.1)
D-Rd daratumumab/lenalidomide/dexamethasone, Rd lenalidomide/
dexamethasone.
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With longer follow-up, the safety profile of D-Rd and Rd
remains largely consistent with the known safety profiles of
daratumumab [26] and of Rd [20, 27, 28]. Despite the
higher rates of neutropenia and infections (upper respiratory
tract infection and pneumonia), the rates of grade 3 or 4
infections were similar between treatment groups and were
managed according to local institutional treatment standard-
of-care protocols. Consistent tolerability was also observed
with daratumumab in the phase 3 MAIA study of D-Rd
versus Rd in patients with NDMM who are ineligible for
transplantation (median follow-up, 28 months) [15].
Taken together, the results from >3.5 years of median
follow-up demonstrate that D-Rd continues to provide sig-
nificant PFS benefit and induces deeper and more durable
responses, including a greater than five-fold increase in the
rate of MRD negativity versus Rd alone in patients with
RRMM. No new safety concerns were observed following a
median of 34 months of D-Rd exposure. These updated
findings continue to support the use of D-Rd in patients
with RRMM after first relapse.
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